Sat., 10/6/12 General Interest, PAPER #104, 2:13 pm OTA-2012
Prevalence of Vitamin D Insufficiency in Orthopaedic Trauma Patients
Brett D. Crist, MD, FACS; Michael A. Hood, MD; Gregory J. Della Rocca, MD, PhD;
James P. Stannard, MD; David A. Volgas, MD; Yvonne M. Murtha, MD;
University of Missouri, Columbia, Missouri, USA
Purpose: This study was conducted to determine the prevalence of vitamin D deficiency or insufficiency in orthopaedic trauma patients.
Methods: A retrospective medical record review was done of all orthopaedic trauma patients above the age of 18 years managed at a university Level I trauma center from January 1, 2009 to September 30, 2010 to identify patients that had a documented 25-hydroxyvitamin D level. Vitamin D deficiency was defined as a 25-hydroxyvitamin D level of less than 20 ng/mL and insufficiency was defined as a level between 20 and 32 ng/mL.
Results: 889 of 1830 patients had a documented 25-hydroxyvitamin D level. Vitamin D deficiency had an overall prevalence of 39%. Combined deficiency and insufficiency had an overall prevalence of 77.4%. 18- to 25-year-olds had the lowest prevalence of deficiency at 29.1% (P = 0.25) and insufficiency at 54.7% (P = 0.08). 36- to 55-year-olds had higher prevalence of deficiency and insufficiency but not statistically significant. Females aged 18 to 25 had lower prevalence of deficiency (25%, P = 0.41) and insufficiency (41.7%, P = 0.16) among females. Males aged 18 to 25 had a lower prevalence of insufficiency (59.7%, P = 0.24) among males.
Conclusion: Vitamin D deficiency and insufficiency were prevalent in this large population of orthopaedic trauma patients. This is the largest known patient population of orthopaedic trauma patients to be evaluated for vitamin D deficiency. Our study time frame of 21 months helps account for seasonal variation in the prevalence of vitamin D deficiency. Establishing the incidence of vitamin D deficiency in a trauma population raises awareness of the disease, and should change screening and treatment patterns.
Alphabetical Disclosure Listing (808K PDF)
• The FDA has not cleared this drug and/or medical device for the use described in this presentation (i.e., the drug or medical device is being discussed for an “off label” use). ◆FDA information not available at time of printing. Δ OTA Grant.